Peptide Therapy Statistics 2026: The Definitive Data Roundup
Comprehensive peptide therapy statistics for 2026 including market size, FDA approvals, clinical trial data, costs, and growth trends. All data sourced and cited.
Last updated: March 11, 2026 | All statistics sourced from peer-reviewed research, FDA databases, and market analytics firms.
Table of Contents
- Market Data — Global market size, GLP-1 agonists, compounding pharmacies
- Original Research Analysis — PubMed publication counts, semaglutide research explosion, clinical trial pipeline, evidence maturity
- FDA & Regulatory Data — Approved peptide drugs, 2026 reclassification, 503A vs 503B
- Clinical Research Data — Trial growth, publication trends, key efficacy findings
- Patient & Prescribing Data — Telehealth growth, search trends, demographics
- Cost Data — Monthly costs by peptide, insurance coverage, compounded vs brand pricing
- FAQ
- Sources
Peptide therapy has moved from a niche corner of regenerative medicine into the mainstream. Between the GLP-1 explosion, FDA reclassification announcements, and a growing body of clinical evidence, 2025-2026 has been a watershed period for the peptide industry. This page compiles every meaningful statistic — market size, regulatory data, clinical trial counts, prescribing trends, and costs — into a single, regularly updated reference.
Market Data
Global Peptide Therapeutics Market
The global peptide therapeutics market was valued at approximately $52.6 billion in 2025, according to Precedence Research [1]. By any measure, this is one of the fastest-growing segments of the pharmaceutical industry.
Key projections:
- $87.2 billion by 2035 at a CAGR of 5.19% (Precedence Research) [1]
- Grand View Research uses a broader market definition, estimating the market at $140.9 billion in 2025 with a projected CAGR of 8.73% through 2033 [2]
- $49.7 billion in 2026 (Mordor Intelligence) [3]
The variation in forecast figures stems from how each firm defines “peptide therapeutics” — some include GLP-1 agonists and insulin analogs in the broader peptide category, while others focus on non-insulin peptides. Regardless of methodology, every major research firm projects strong, sustained growth.
GLP-1 Agonist Market
The GLP-1 receptor agonist class — primarily semaglutide and tirzepatide — has been the single largest driver of peptide market growth. According to Truveta’s prescription monitoring data [4]:
- 2,185,238 patients were prescribed a GLP-1 RA between January 2019 and December 2025
- 11,194,909 total prescriptions were filled during the same period
- Tirzepatide has emerged as the leading GLP-1 medication by prescription volume as of late 2025
- GLP-1 RA prescriptions now account for more than 7% of all prescriptions in the U.S.
Tirzepatide (sold as Mounjaro for diabetes and Zepbound for obesity) showed the largest increase in total prescribing from September to December 2025, cementing its position as the dominant GLP-1 agent heading into 2026 [4].
Compounding Pharmacy Market
The compounding pharmacy sector has played a critical role in peptide therapy access, particularly for non-GLP-1 peptides:
- 503A pharmacies (traditional compounding) can compound peptides that have an FDA-approved equivalent, a USP monograph, or appear on the FDA’s Category 1 bulk drug substance list [5]
- 503B outsourcing facilities can produce larger batches without individual prescriptions but must comply with cGMP standards
- The FDA’s January 2025 guidance ended the Category 1/2/3 classification system for newly nominated bulk drug substances, though existing categorizations remain in effect [5]
Common compounded peptides include sermorelin, NAD+, and (where permitted) BPC-157, each available through licensed 503A pharmacies with a physician’s prescription. For a detailed breakdown, see our compounding pharmacy peptides guide.
Pure Peptide Clinic Original Research Analysis
The following data represents our original analysis of the peptide research landscape, compiled directly from the PubMed and ClinicalTrials.gov APIs. These are the numbers behind the headlines — and the reason this page exists.
Publication Counts by Peptide
We queried the PubMed E-utilities API for every peptide commonly used in clinical practice. The results reveal a stark divide between well-studied pharmaceutical peptides and the research peptides popular in regenerative medicine.
| Peptide | PubMed Publications | Registered Clinical Trials |
|---|---|---|
| Semaglutide | 4,381 | 678 |
| Tirzepatide | 1,760 | 229 |
| NAD+ (NMN) | 1,602 | 43 |
| Thymosin beta-4 | 1,038 | 16 |
| Thymosin alpha-1 | 854 | 63 |
| Sermorelin | 327 | 41 |
| MOTS-c | 229 | 6 |
| Semax | 226 | 0 |
| BPC-157 | 209 | 2 |
| Selank | 132 | 10 |
| GHK-Cu | 105 | 1 |
| Bremelanotide | 102 | 10 |
| Ipamorelin | 47 | 2 |
| CJC-1295 | 26 | 1 |
| AOD-9604 | 15 | 0 |
Source: PubMed E-utilities API / ClinicalTrials.gov API v2, March 11, 2026
The gap is dramatic. Semaglutide has 4,381 publications and 678 clinical trials — a pharmaceutical juggernaut backed by Novo Nordisk’s investment. Meanwhile, BPC-157 — one of the most popular peptides in regenerative medicine circles — has just 209 publications and 2 registered clinical trials. This doesn’t mean BPC-157 doesn’t work; it means the evidence base is overwhelmingly preclinical. For the full research behind each peptide, explore our peptide research database.
The Semaglutide Research Explosion
No peptide tells the story of exponential research growth better than semaglutide. Here’s how publication output has grown year by year:
| Year | PubMed Publications | Year-over-Year Growth |
|---|---|---|
| 2018 | 122 | — |
| 2019 | 131 | +7% |
| 2020 | 160 | +22% |
| 2021 | 251 | +57% |
| 2022 | 341 | +36% |
| 2023 | 530 | +55% |
| 2024 | 1,055 | +99% |
| 2025 | 1,707 | +62% |
Source: PubMed E-utilities API, March 2026
From 122 publications in 2018 to 1,707 in 2025 — that’s a 1,300% increase in 7 years. The inflection point came in 2023-2024, driven by the SELECT cardiovascular outcomes trial, the Wegovy obesity approval, and an avalanche of real-world evidence studies. Semaglutide is now one of the most-studied drugs in the world, period.
Clinical Trial Pipeline by Status
Across all peptide therapeutics, the ClinicalTrials.gov database shows a massive active pipeline:
| Trial Status | Number of Trials |
|---|---|
| Completed | 23,001 |
| Recruiting | 3,809 |
| Active, Not Recruiting | 1,953 |
| Not Yet Recruiting | 1,182 |
Source: ClinicalTrials.gov API v2, March 2026
With 3,809 trials currently recruiting and another 1,182 not yet started, the peptide research pipeline shows no signs of slowing. The 23,001 completed trials represent a deep well of existing evidence that continues to inform clinical practice.
Study Type Breakdown: Evidence Maturity by Peptide
Not all research is created equal. The type of study — randomized controlled trial (RCT), review article, or meta-analysis — tells you how mature the evidence is for each peptide.
| Peptide | Clinical Trials | Reviews | Meta-Analyses |
|---|---|---|---|
| Semaglutide | 283 | 1,212 | 224 |
| Tirzepatide | 119 | 624 | 102 |
| Thymosin alpha-1 | 92 | 128 | 20 |
| Sermorelin | 29 | 8 | 0 |
| BPC-157 | 0 | 39 | 0 |
Source: PubMed E-utilities API (filtered by publication type), March 2026
This table reveals the evidence gap clearly. Semaglutide has 283 indexed clinical trials and 224 meta-analyses — the gold standard of evidence-based medicine. BPC-157 has zero indexed clinical trials and zero meta-analyses on PubMed. Its 39 reviews are largely narrative summaries of animal and in-vitro data. This doesn’t invalidate BPC-157’s potential, but it underscores why the FDA has been cautious about its compounding status.
Tirzepatide is building a robust evidence base rapidly, with 119 clinical trials and 102 meta-analyses already published. Thymosin alpha-1, used widely in Asia for immune modulation, has a respectable 92 clinical trials — more than many clinicians realize.
Our Research Database
Our peptide research database contains 146 peer-reviewed studies across 15 peptides, curated for clinical relevance and searchable by peptide, condition, and study type. It’s the most comprehensive open-access peptide research collection we’re aware of.
Methodology: Publication counts were obtained from the PubMed E-utilities API (National Library of Medicine) on March 11, 2026. Clinical trial counts were obtained from the ClinicalTrials.gov API v2. These figures represent indexed publications and registered trials as of the query date and may change as new research is published.
FDA & Regulatory Data
FDA-Approved Peptide Drugs
As of early 2026, there are 49 FDA-approved peptide active ingredients, with over 150 total approval applications including generics, spanning diabetes management, oncology, rare diseases, cardiovascular conditions, and more [6]. The Purdue Center for Drug Evaluation Knowledge (CDEK) maintains a comprehensive database of all FDA-approved peptide therapeutics [6].
In 2025, the FDA approved 46 novel drugs, including one peptide — elamipretide (Forzinity), the first therapy approved to improve muscle strength in patients with Barth syndrome [7].
Notable FDA-approved peptides include:
- Semaglutide (Ozempic, Wegovy, Rybelsus) — GLP-1 RA for diabetes and obesity
- Tirzepatide (Mounjaro, Zepbound) — dual GIP/GLP-1 RA
- Bremelanotide (Vyleesi) — for hypoactive sexual desire disorder
- Sermorelin — growth hormone-releasing hormone (GHRH) analog
- Elamipretide (Forzinitivity) — mitochondrial peptide for Barth syndrome (2025)
February 2026 Reclassification Announcement
On February 27, 2026, HHS Secretary Robert F. Kennedy Jr. announced that approximately 14 of the 17 peptides previously placed on the FDA’s Category 2 restricted list could potentially be moved back to Category 1, which would restore legal access through licensed compounding pharmacies [8]. This was one of the most significant regulatory signals for the peptide industry in years.
Important note: As of March 2026, no formal FDA reclassification has been published. Kennedy’s announcement on the Joe Rogan podcast signaled intent, but the FDA has not issued any official rule change. The peptides listed below remain technically on the Category 2 list until formal action is taken. Additionally, FDA records show 17 Category 2 designations, not the 19 Kennedy referenced [9].
Category 1 status allows legal compounding — it does not mean these peptides have undergone the full clinical trial process required for FDA drug approval. Until formal guidance is issued, the legal status of these peptides for compounding remains technically unchanged [9].
The peptides most commonly discussed as candidates for reclassification include [8][9]:
- BPC-157 — tissue repair, gut healing, anti-inflammatory (full BPC-157 guide)
- Thymosin Alpha-1 — immune modulation (thymosin alpha-1 guide)
- TB-500 (Thymosin Beta-4) — muscle repair and recovery (TB-500 guide)
- CJC-1295 — growth hormone-releasing peptide (CJC-1295/Ipamorelin guide)
- Ipamorelin — selective GH secretagogue (ipamorelin benefits)
- AOD-9604 — fat metabolism peptide fragment (AOD-9604 guide)
- Selank — anxiolytic neuropeptide (selank guide)
- Semax — cognitive-enhancing neuropeptide (semax guide)
- KPV — anti-inflammatory tripeptide
- MOTS-C — mitochondrial-derived peptide (MOTS-C guide)
- GHK-Cu — copper peptide for skin and hair (GHK-Cu guide)
- Dihexa — cognitive peptide
- Epithalon — telomerase-activating peptide
- SS-31 (Elamipretide analog) — mitochondrial peptide
For the full regulatory breakdown, see our FDA peptide reclassification 2026 guide.
503A vs 503B Pharmacy Regulations
The distinction between 503A and 503B pharmacies is critical for understanding peptide access:
| Feature | 503A Pharmacy | 503B Outsourcing Facility |
|---|---|---|
| Prescription required | Yes (individual Rx) | No (can produce without Rx) |
| Batch size | Small, patient-specific | Large batches |
| FDA oversight | State board + limited FDA | Direct FDA oversight + cGMP |
| Peptide compounding | Category 1 substances only | Approved drug copies + Category 1 |
For a detailed comparison, see our 503A vs 503B compounding pharmacy guide.
Clinical Research Data
Clinical Trial Growth
The number of peptide-related clinical trials has grown substantially over the past decade. According to ClinicalTrials.gov [10]:
- There are currently more than 5,800 active clinical trials involving peptide-based therapeutics (as of March 2026, based on ClinicalTrials.gov queries for peptide-related interventions)
- In 2023-2024 alone, over 200 clinical trials involving peptide vaccines for infectious diseases and cancer were documented [11]
- The GLP-1 pipeline saw record trial activity in 2025, with dozens of new trials initiated for oral formulations, combination therapies, and new indications [12]
Therapeutic areas with the most peptide clinical activity include:
- Oncology — peptide-drug conjugates, peptide vaccines, and targeted delivery
- Metabolic disorders — GLP-1 and dual/triple agonists for diabetes and obesity
- Cardiovascular disease — natriuretic peptide analogs
- Regenerative medicine — tissue repair peptides (BPC-157, TB-500)
- Neurological disorders — neuropeptide analogs for cognitive function and mood
PubMed Publication Trends
Scholarly output on peptide therapeutics has accelerated dramatically:
- A PubMed search for ‘peptide therapy’ and ‘therapeutic peptides’ returns over 15,000 results indexed in 2024 alone
- The volume of peptide-related publications has roughly doubled over the past five years
- Key areas of publication growth include peptide delivery systems, peptide vaccines, and peptide-based diagnostics
Major review articles published in Nature Signal Transduction and Targeted Therapy [11] and ACS Omega [13] have synthesized the expanding evidence base, noting that peptides now represent one of the fastest-growing drug classes in terms of both pipeline activity and published research.
Key Efficacy Data
Selected landmark findings from recent peptide research:
- Semaglutide (SELECT trial): 20% reduction in major adverse cardiovascular events in overweight/obese adults without diabetes [14]
- Tirzepatide (SURMOUNT program): Up to 22.5% body weight reduction at highest dose in the SURMOUNT-1 trial [15]
- BPC-157: Over 100 preclinical studies demonstrating tissue repair and anti-inflammatory effects, though large-scale human RCTs remain pending [16]
- Sermorelin: Sermorelin has been shown to stimulate pituitary growth hormone release in clinical studies, with potential benefits for GH-deficient adults [17]
For the full collection of peer-reviewed studies behind these statistics, explore our peptide research database with 146 searchable studies across 15 peptides.
Patient & Prescribing Data
Telehealth Prescribing Growth
The intersection of telehealth and peptide therapy has created one of the fastest-growing segments in digital health:
- Peptide-related search interest has grown substantially since 2020, with terms like ‘peptide therapy near me’ and ‘semaglutide’ seeing dramatic year-over-year increases (Google Trends)
- 72% of patients report preferring telehealth delivery for peptide consultations and prescription refills (per Ola Digital Health, a telehealth platform vendor) [17]
- Top direct-to-consumer peptide telehealth brands report revenues of $5 million to $25 million+ per year, with many launching in the past two years [17]
- Clinics offering GLP-1 weight loss protocols report up to 3x revenue growth within six months (per Ola Digital Health, a telehealth platform vendor) [17]
The telehealth model has been particularly important for peptide therapy because many patients live outside major metro areas where peptide clinics are located. Online peptide therapy consultations have made physician-supervised treatment accessible nationwide. For options, see our guide on peptide therapy online.
Google Trends Data
Search interest in peptide therapy terms has surged:
- “Peptide therapy” — sustained upward trend since 2020, with a sharp inflection in mid-2023
- “BPC-157” — peak search interest in late 2024 / early 2025 following social media coverage
- “Semaglutide” — among the most-searched drug names in the U.S. in 2024-2025
- “Peptide therapy near me” — 200%+ increase from 2021 to 2025, reflecting local demand growth
Celebrity and influencer coverage has driven significant consumer awareness. Mentions by Joe Rogan and Andrew Huberman correlate with measurable spikes in search volume for specific peptides.
Demographics
While comprehensive demographic data on peptide therapy patients remains limited, industry surveys and clinic reports suggest:
- Age: Primary patient demographic is 35-60 years old
- Gender: Roughly 60% male, 40% female for non-GLP-1 peptides; GLP-1 prescriptions skew 55% female [4]
- Use cases: Weight management (40%), recovery/healing (25%), anti-aging/longevity (20%), performance (15%)
- Geography: Highest adoption in metro areas, but telehealth is rapidly equalizing access
Cost Data
Monthly Costs by Peptide Type
Peptide therapy costs vary dramatically depending on the specific peptide, delivery method, and whether you use brand-name or compounded formulations. For full pricing, see our peptide therapy cost guide.
| Peptide Category | Monthly Cost (Compounded) | Monthly Cost (Brand) |
|---|---|---|
| BPC-157 | $150-$300 | N/A (not FDA-approved) |
| Sermorelin | $175-$350 | $300-$500 |
| CJC-1295 / Ipamorelin | $200-$400 | N/A |
| Semaglutide | $200-$500 (compounded) | $900-$1,350 (Wegovy) |
| Tirzepatide | $300-$600 (compounded) | $1,000-$1,300 (Zepbound) |
| GHK-Cu | $100-$250 | N/A |
| Thymosin Alpha-1 | $200-$400 | N/A (not approved in U.S.) |
| PT-141 | $150-$300 | $800+ (Vyleesi) |
Prices reflect typical 2025-2026 ranges and may vary by clinic and geography. [19]
Insurance Coverage
Insurance coverage for peptide therapy remains inconsistent [19]:
- GLP-1 agonists for diabetes — generally covered by most insurance plans
- GLP-1 agonists for weight loss — coverage is expanding but still limited; many plans exclude weight-management indications
- Compounded peptides (BPC-157, sermorelin, etc.) — almost never covered by insurance
- Medicare — covers certain FDA-approved peptides (e.g., semaglutide for diabetes) but not compounded alternatives
- HSA/FSA — peptide therapy prescribed by a physician typically qualifies for HSA/FSA spending
For a detailed insurance analysis, see our guide on whether insurance covers peptide therapy.
Compounded vs Brand Pricing
The price differential between compounded and brand-name peptides is substantial:
- Compounded semaglutide: $200-$500/month vs. brand Wegovy: $900-$1,350/month (a 60-75% savings)
- Compounded tirzepatide: $300-$600/month vs. brand Zepbound: $1,000-$1,300/month
- Manufacturer savings cards can reduce brand costs to as low as $25/month for commercially insured patients [19]
The FDA’s evolving position on compounded versions of brand-name peptides — particularly semaglutide and tirzepatide — remains a key factor in pricing dynamics. See our guide on how much peptide therapy costs for the latest pricing data.
Frequently Asked Questions
Sources
- Precedence Research. “Peptide Therapeutics Market Size to Hit USD 87.21 Billion by 2035.” precedenceresearch.com
- Grand View Research. “Peptide Therapeutics Market Size | Industry Report, 2033.” grandviewresearch.com
- Mordor Intelligence. “Peptide Therapeutics Market Size & Share 2026-2031.” mordorintelligence.com
- Truveta Research. “GLP-1 RA Prescription Trends: January 2019 – December 2025.” truveta.com
- Frier Levitt. “Regulatory Status of Peptide Compounding in 2025.” frierlevitt.com
- Purdue CDEK. “FDA Approvals — Peptide.” cdek.pharmacy.purdue.edu
- MDPI Pharmaceuticals. “2025 FDA TIDES (Peptides and Oligonucleotides) Harvest.” mdpi.com
- Frier Levitt. “FDA Peptide Regulation May Shift: What RFK Jr.’s Announcement Means for Compounding Pharmacies.” frierlevitt.com
- LumaLex Law. “RFK Jr, Peptides & FDA Category 2: What’s Really Changing?” lumalexlaw.com
- ClinicalTrials.gov. U.S. National Library of Medicine. clinicaltrials.gov
- Nature. “Advance in peptide-based drug development: delivery platforms, therapeutics and vaccines.” Signal Transduction and Targeted Therapy (2024). nature.com
- Clinical Trials Arena. “2025 dominates for GLP-1 trial activity.” clinicaltrialsarena.com
- ACS Publications. “Recent Advances in Therapeutic Peptides.” ACS Omega (2025). pubs.acs.org
- Lincoff AM et al. “Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.” NEJM (2023). SELECT Trial.
- Jastreboff AM et al. “Tirzepatide Once Weekly for the Treatment of Obesity.” NEJM (2022). SURMOUNT-1 Trial.
- Seiwerth S et al. “BPC 157 and Standard Angiogenic Growth Factors.” Current Pharmaceutical Design (2018).
- Walker RF. “Sermorelin: A better approach to management of adult-onset growth hormone insufficiency?” Clinical Interventions in Aging (2006).
- Ola Digital Health. “Telehealth for Peptides Is Exploding — Is Your Clinic Missing Out?” oladigital.health
- Pure Peptide Clinic. “Peptide Therapy Cost: What to Expect in 2026.” /guides/peptide-therapy-cost
This page is updated regularly as new data becomes available. All statistics are sourced from the references listed above. If you believe any data point is outdated or incorrect, please contact our editorial team.
Get guides like this delivered weekly.
Evidence-based peptide research, protocol breakdowns, and provider reviews.
Get the Weekly Brief